Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase

Vascular Pharmacology

Volumn 53, Issue 5-6, 2010, Pages 281-287

  Roger, Séverine ^a   Paysant, Jérôme ^a   Badier Commander, Cécile ^a   Cordi, Alex ^a   Verbeuren, Tony J ^a   Félétou, Michel ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Aggregation; BAY 58 2667; Nitric oxide; Prostacyclin; Soluble guanylyl cyclase

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; ADENOSINE DIPHOSPHATE; BERAPROST; COLLAGEN; CYCLIC AMP; CYCLIC GMP; HYDROXOCOBALAMIN; ISOBUTYLMETHYLXANTHINE; N(G) NITROARGININE;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INCUBATION TIME; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION;

ANIMALS; BENZOIC ACIDS; CYCLIC AMP; CYCLIC GMP; ENZYME ACTIVATORS; EPOPROSTENOL; GUANYLATE CYCLASE; MALE; NITRIC OXIDE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RATS; RATS, INBRED WKY;

EID: 78349309565     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2010.09.008     Document Type: Article

References (33)

1. Alonso-Alija C., Heil M., Flubacher D., Naab P., Stasch J.-P., Wunder F., Dembowsky K., Perzborn E., Stahl E. Novel derivatives of dicarboxylic acid having pharmaceutical properties 2001, WO-119780-A 2001.03.22.
2. Anfossi G., Russo I., Massucco P., Mattiello L., Balbo A., Cavalot F., Trovati M. Studies on inhibition of human platelet function by sodium nitroprusside. Kinetic evaluation of the effect on aggregation and cyclic nucleotide content. Thromb. Res. 2001, 102:319-330.
3. Dickinson N.T., Jang E.K., Haslam R.J. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation. Biochem. J. 1997, 323. 371-317.
4. Evgenov O.V., Pacher P., Schmidt P.M., Haskó G., Schmidt H.H., Stasch J.-P. NO-independent stimulators and activators of soluble guanylyl cyclase: discovery and therapeutic potential. Nat. Rev. Drug Discov. 2006, 5:755-768.
5. Feijge M.A., Ansink K., Vanschoonbeek K., Heemskerk J.W. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3. Biochem. Pharmacol. 2004, 67:1559-1567.
6. Félétou M., Vanhoutte P.M. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H985-H1002.
7. Friebe A., Müllershausen F., Smolenski A., Walter U., Schultz G., Koesling D. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol. Pharmacol. 1998, 54:962-967.
8. Garthwaite J., Southam E., Boulton C.L., Nielsen E.B., Schmidt K., Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1, 2, 4]oxadiazolo[4, 3-a]quinoxalin-1-one. Mol. Pharmacol. 1995, 48:184-188.
9. Gomez E., Schwendemann C., Roger S., Simonet S., Paysant J., Courchay C., Verbeuren T.J., Félétou M. Aging and prostacyclin responses in aorta and platelets from WKY and SHR rats. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H2198-H2211.
10. Hobbs A.J., Moncada S. Antiplatelet properties of a novel, non-NO-based soluble guanylyl cyclase activator, BAY 41-2272. Vasc. Pharmacol. 2003, 40:149-154.
11. Ignarro L.J. Heme-dependent activation of guanylyl cyclase by nitric oxide: a novel signal transduction mechanism. Blood Vessels 1991, 28:67-73.
12. Lidbury P.S., Antunes E., de Nucci G., Vane J.R. Interactions of iloprost and sodium nitroprusside on vascular smooth muscle and platelet aggregation. Br. J. Pharmacol. 1989, 98:1275-1280.
13. Loeb A.L., Gear A.R. Potentiation of platelet aggregation by atrial natriuretic peptide. Life Sci. 1988, 43:731-738.
14. Lucas K.A., Pitari G.M., Kazerounian S., Ruiz-Stewart I., Park J., Schulz S., Chepenik K.P., Waldman S.A. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev. 2000, 52:375-414.
15. Martin F., Baskaran P., Ma X., Dunten P.W., Schaefer M., Stasch J.P., Beuve A., van den Akker F. Structure of cinaciguat (bay 58-2667) bound to nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase. J. Biol. Chem. 2010, 285:22631-22637.
16. Maurice D.H., Haslam R.J. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol. Pharmacol. 1990, 37:671-681.
17. Mergia E., Koesling D., Friebe A. Genetic mouse models of the NO receptor 'soluble' guanylyl cyclases. Handb. Exp. Pharmacol. 2009, 191:33-46.
18. Negrescu E.V., Grünberg B., Kratzer M.A., Lorenz R., Siess W. Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside. Cardiovasc. Drugs Ther. 1995, 9:619-629.
19. Reep B.R., Lapetina E.G. Nitric oxide stimulates the phosphorylation of rap1b in human platelets and acts synergistically with iloprost. Biochem. Biophys. Res. Commun. 1996, 219:1-5.
20. Roger C., Badier-Commander C., Paysant J., Cordi A., Verbeuren T.J., Félétou M. The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide. Br. J. Pharmacol. 2001, 161:1044-1058.
21. Roy B., Halvey E.J., Garthwaite J. An enzyme-linked receptor mechanism for nitric oxide-activated guanylyl cyclase. J. Biol. Chem. 2008, 283:18841-18851.
22. Roy B., Mo E., Vernon J., Garthwaite J. Probing the presence of the ligand-binding haem in cellular nitric oxide receptors. Br. J. Pharmacol. 2008, 153:1495-1504.
23. Schmidt P., Schramm M., Schröder H., Stasch J.-P. Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. Eur. J. Pharmacol. 2003, 468:167-174.
24. Schmidt H.H., Schmidt P.M., Stasch J.-P. NO- and haem-independent soluble guanylyl cyclase activators. Handb. Exp. Pharmacol. 2009, 191:309-339.
25. Sim A.K., McCraw A.P., Cleland M.E., Nishio S., Umetsu T. Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation. Arzneim. Forsch. 1985, 35:1816-1818.
26. Smyth E.M., FitzGerald G.A. Human prostacyclin receptor. Vitam. Horm. 2002, 65:149-165.
27. Stasch J.-P., Hobbs A.J. NO-independent, haem-dependent soluble guanylyl cyclase stimulators. Handb. Exp. Pharmacol. 2009, 191:277-308.
28. Stasch J.-P., Becker E.M., Alonso-Alija C., Apeler H., Dembowsky K., Feurer A., Gerzer R., Minuth T., Perzborn E., Pleiss U., Schröder H., Schroeder W., Stahl E., Steinke W., Straub A., Schramm M. NO-independent regulatory site on soluble guanylyl cyclase. Nature 2001, 410:212-215.
29. Stasch J.-P., Alonso-Alija C., Apeler H., Dembowsky K., Feurer A., Minuth T., Perzborn E., Schramm M., Straub A. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br. J. Pharmacol. 2002, 135:333-343.
30. Stasch J.-P., Schmidt P., Alonso-Alija C., Apeler H., Dembowsky K., Haerter M., Heil M., Minuth T., Perzborn E., Pleiss U., Schramm M., Schroeder W., Schröder H., Stahl E., Steinke W., Wunder F. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br. J. Pharmacol. 2002, 136:773-783.
31. Stasch J.-P., Schmidt P.M., Nedvetsky P.I., Nedvetskaya T.Y.Arun, Kumar H.S., Meurer S., Deile M., Taye A., Knorr A., Lapp H., Müller H., Turgay Y., Rothkegel C., Tersteegen A., Kemp-Harper B., Müller-Esterl W., Schmidt H.H.H.W. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J. Clin. Invest. 2006, 116. 2552-2261.
32. Walter U., Eigenthaler M., Geiger J., Reinhard M. Role of cyclic nucleotide-dependent protein kinases and their common substrate VASP in the regulation of human platelets. Adv. Exp. Med. Biol. 1993, 344:237-249.
33. Wu C.C., Ko F.N., Kuo S.C., Lee F.Y., Teng C.M. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylyl cyclase. Br. J. Pharmacol. 1995, 116:1973-1978.